Concurrently, the PI3K-AKT-mTOR pathway is aberrantly activated in prostate cancer, driving tumor growth and treatment resistance by regulating proliferation, survival, and metabolic reprogramming. The gene discussed is AKT1; the disease is prostate carcinoma.